{"url_path":"/sec/adil/8-k/2026-06-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-067711-index.html","accession_number":"0001213900-26-067711","cik":"0001513525","ticker":"ADIL","issuer_name":"ADIAL PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-067711-index.html","primary_entity_key":"0001513525","primary_entity_name":"ADIAL PHARMACEUTICALS, INC."},"word_count":305,"has_tables":true,"body_markdown":"false\n--12-31\n0001513525\n\n0001513525\n\n2026-06-11\n2026-06-11\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\n \n\nDate of Report (date of earliest event reported):\n**June 11, 2026**\n\n \n\n**Adial Pharmaceuticals, Inc.**\n\n*(Exact name of registrant as specified in charter)*\n\n \n\n**Delaware**\n\n*(State or other jurisdiction of incorporation)*\n\n \n\n**001-38323**\n \n**82-3074668**\n\n*(Commission\nFile Number)*\n \n*(IRS\nEmployer Identification No.)*\n\n** **\n\n**4870 Sadler Road, Ste 300**\n\n**Glen Allen, VA 23060**\n\n*(Address of principal executive offices and\nzip code)*\n\n \n\n**(804) 487-8196**\n\n*(Registrant’s telephone number including\narea code)*\n\n* *\n\n* *\n\n*(Former Name and Former Address)*\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:\n\n \n\n☐\nWritten communications\npursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant\nto Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading\nSymbols**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock\n \nADIL\n \n\nThe Nasdaq Stock Market LLC\n\n((Nasdaq Capital Market)\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of\nthe Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by checkmark\nif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ☐"}